Jane Street Group LLC Cuts Stock Holdings in AlloVir, Inc. (NASDAQ:ALVR)

Jane Street Group LLC lowered its stake in AlloVir, Inc. (NASDAQ:ALVR) by 51.8% during the 3rd quarter, Holdings Channel reports. The firm owned 83,351 shares of the company’s stock after selling 89,680 shares during the quarter. Jane Street Group LLC’s holdings in AlloVir were worth $67,000 at the end of the most recent reporting period.

Separately, Cubist Systematic Strategies LLC increased its holdings in shares of AlloVir by 152.3% in the second quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock worth $36,000 after purchasing an additional 30,072 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

AlloVir Trading Down 4.7 %

Shares of AlloVir stock opened at $0.38 on Thursday. The firm has a market cap of $44.04 million, a PE ratio of -0.43 and a beta of 0.65. The stock has a 50 day moving average of $0.52 and a 200 day moving average of $0.69. AlloVir, Inc. has a 12 month low of $0.38 and a 12 month high of $1.05.

AlloVir (NASDAQ:ALVR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.